Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIBIT-ML1: Nivolumab + Ipilimumab +/- Guadecitabine in Resistant Melanoma/NSCLC
NCT04250246Phase 2Unknown
- Sponsor
- NIBIT Foundation
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine in melanoma, non-small cell lung cancer (NSCLC), sponsored by NIBIT Foundation. Status: unknown.
02
Drugs
guadecitabine
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04250246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250246.